Nucleic acid molecule, polypeptide, protein, related product and application

By designing RNA molecules containing HPV E5, E6 and E7 coding regions, combining specific UTR sequences and polyadenylate tails, an efficient mRNA vaccine was constructed, and the truncated fusion junction optimization technology was used to solve the existing HPV therapeutic vaccine targets. The problems of low coverage and immune escape have achieved effective target coverage and tumor suppression of HPV16 and HPV18.

CN118910042APending Publication Date: 2024-11-08SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410810613.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-20
Filing Date
2024-06-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing treatment of HPV-related diseases, especially therapeutic vaccines for cervical cancer, have low target coverage of high-risk HPV16 and HPV18, and have immune escape problems, making it difficult to effectively inhibit tumor growth.

Method used

Provides an RNA molecule, which contains the coding region encoding HPV E5, E6 and E7 proteins, and combines specific UTR sequences and polyadenylate tails, to construct efficient mRNA vaccines that reduce toxicity by introducing organ-specific miRNA target sequences. And the truncated fusion link optimization protein technology is used to enhance immune response and drug efficacy.

Benefits of technology

It improves the target coverage of high-risk HPV16 and HPV18, enhances cellular immune response, significantly inhibits tumor growth, reduces the toxicity and integration risks of vaccines, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910042A_ABST
    Figure CN118910042A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of molecular biological medicines, in particular to a nucleic acid molecule, polypeptide, protein, related products and application. The invention provides a novel vaccine for treating HPV positive diseases by taking oncogenes E5, E6 and E7 of high-risk HPV16 and HPV18 as targets, and the vaccine is wide in target, higher in disease group coverage rate, strong in immunogenicity, capable of fully activating cellular immunity and good in product efficacy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent application No. 2023107435817, filed on June 21, 2023, with invention name “RNA molecules and their products and uses”, the entire contents of which are incorporated by reference into this application.

[0002] This application claims priority to Chinese patent application No. 2023117624707, filed on December 20, 2023, with invention name “RNA molecules and their products and uses”, the entire contents of which are incorporated by reference into this application. Technical Field

[0003] The present invention relates to the field of molecular biomedicine technology, and in particular to a nucleic acid molecule, a polypeptide, a protein, and related products and uses. Background Art

[0004] According to statistics from the World Health Organization: Worldwide, cancers caused by human papillomavirus (HPV) infection account for about 5% of all cancers, and an estimated 625,600 women and 69,400 men develop HPV-related cancers each year. Despite progress in vaccination and screening methods for the prevention and diagnosis of early cancers, the treatment of HPV-related high-risk diseases, especially cervical precancerous lesions, cervical cancer, and oropharyngeal cancer, is still a disease with a large unmet need. Among them, HPV is associated with the incidence of cervical cancer, and 90% of cervical cancers are closely related to persistent infection with high-risk HPV, among which HPV16 and 18 have the highest correlation. Cervical cancer therapeutic vaccines are aimed at patients with HPV infection, mainly targeting high-risk HPV16 and 18. Summary of the invention

[0005] The present invention provides a nucleic acid molecule, and its corresponding polypeptide, protein, related products, and related uses.

[0006] Specifically, the technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention provides an RNA molecule comprising:

[0008] (a) a coding region encoding a polypeptide; and

[0009] (b) a 5'UTR upstream of the coding region; and

[0010] (c) a 3'UTR downstream of the coding region;

[0011] The constituent sequence of the 3'UTR comprises a nucleotide fragment derived from a histone gene.

[0012] UTR is a key element of eukaryotic mRNA and directly affects the expression of target genes. Among them, 5'UTR is crucial for the initiation of protein translation. Typical cap-dependent translation initiation usually starts with the recruitment of ribosomes to the 5' cap by eukaryotic mRNA, followed by ribosome scanning towards the start codon. The sequence and structure of 3'UTR in mRNA determine their stability, localization and expression. 3'UTR regulatory elements are recognized by a variety of trans-acting factors, including miRNA and its related structures and RBP (RNA-BINDING PROTEINS). Therefore, constructing and screening efficient UTRs is an essential step in the development of mRNA drugs.

[0013] The composition sequence of the 3'UTR of the RNA molecule provided by the present invention includes nucleotide fragments derived from histone genes. The 3'UTR sequence constructed from nucleotide fragments derived from histone genes can obtain a higher translation efficiency and can translate the target gene into protein in the case of complete lack of Poly A.

[0014] Preferably, the nucleotide fragment of the histone gene derived from the 3'UTR downstream sequence is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 28-39.

[0015] Preferably, the 3'UTR upstream sequence is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 19-27.

[0016] Preferably, the constituent sequence of the 3'UTR further comprises a miRNA target sequence.

[0017] In the present invention, the miRNA target sequence refers to the complementary sequence of the organ-specific highly expressed miRNA. Introducing the organ-specific highly expressed miRNA target sequence into the composition sequence of the 3'UTR helps to reduce the side effects of the target gene (especially cytokines that cause immune response) and promote the degradation of mRNA drugs in the corresponding organs.

[0018] Preferably, the miRNA target sequence is not located at the end of the 3'UTR. The present invention preferably inserts the miRNA into the front end or middle position of the 3'UTR sequence to better exert its inhibitory effect on mRNA expression in specific organs, thereby reducing the toxicity of mRNA drugs.

[0019] Preferably, the miRNA target sequence is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 43-110.

[0020] Preferably, the nucleotide fragment of the 5'UTR is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 1-18.

[0021] Furthermore, although the RNA molecule provided by the present invention can translate the target gene into protein without a polyadenylic acid tail, in a preferred embodiment of the present invention, the RNA molecule further comprises:

[0022] (d) Polyadenylic acid tail at the 3' end.

[0023] Preferably, the length of the poly(A) tail is 0-200 bp;

[0024] Alternatively, the poly(A) tail has a length of 0-150 bp;

[0025] Alternatively, the poly(A) tail has a length of 30-200 bp.

[0026] Preferably, the nucleotide sequence of the RNA molecule is as shown in any one of SEQ ID NOs: 111-121.

[0027] In a second aspect, the present invention further provides an RNA molecule comprising:

[0028] (a) a coding region encoding a polypeptide; and

[0029] (b) a 5'UTR upstream of the coding region; and

[0030] (c) a 3'UTR downstream of the coding region;

[0031] The polypeptide encoded by the coding region comprises an amino acid fragment derived from HPV E5 protein, and further comprises:

[0032] Amino acid fragments derived from HPV E6 protein; and / or

[0033] Amino acid fragments derived from HPV E7 protein.

[0034] E6 protein and E7 protein are related to the functional inactivation of major cell cycle regulators, tumor transformation inhibitors and telomerase activation. The existing therapeutic vaccines for HPV-positive tumor patients mainly target E6 and E7 of HPV16 and / or HPV18, with fewer targets and low coverage of disease groups. The mRNA vaccine targets provided by the present invention include E6 and E7 of high-risk HPV16 and HPV18, and also add HPV16E5 and HPV18 E5 that can promote immune escape. It helps to increase the product coverage of disease groups and improve the efficacy of the product.

[0035] The E5 protein can promote keratinocyte differentiation and immune escape. Although the E5 protein is weakly carcinogenic and is unlikely to be directly involved in carcinogenesis, the E5 protein can enhance the carcinogenicity of the major transforming proteins E6 and E7 in animal model studies. The expression of the E5 protein disrupts the synthesis and function of major histocompatibility complex (MHC) class I and class II proteins. MHC class I downregulation can promote immune cell escape by preventing cytotoxic T lymphocytes from recognizing infected cells. E5 is essential for the cancerous transformation of cells when interacting with E6 and E7. The polypeptide encoded by the RNA molecule coding region of the present invention includes the E5 protein of HPV (i.e., the E5 gene is added to the RNA molecule coding region), which, when used as a therapeutic vaccine drug, targets a wider range of targets than the prior art.

[0036] Further, in the present invention, the amino acid sequence of the HPV E5 protein is selected from the amino acid sequence of the HPV16-E5 protein and / or the amino acid sequence of the HPV18-E5 protein;

[0037] The amino acid sequence of the HPV E6 protein is selected from the group consisting of the amino acid sequence of the HPV16-E6 protein and / or the amino acid sequence of the HPV18-E6 protein;

[0038] The amino acid sequence of the HPV E7 protein is selected from the amino acid sequence of the HPV16-E7 protein and / or the amino acid sequence of the HPV18-E7 protein.

[0039] Preferably, the HPV E5 protein is selected from the N-terminus or C-terminus of the HPV16-E5 protein and / or the HPV18-E5 protein;

[0040] The HPV E6 protein is selected from the N-terminus or C-terminus of the HPV16-E6 protein and / or the HPV18-E6 protein;

[0041] The HPV E7 protein is selected from the N-terminus or C-terminus of the HPV16-E7 protein and / or the HPV18-E7 protein;

[0042] Preferably, the sequence of the N-terminus or C-terminus of the HPV16-E5 protein is SEQ ID NO: 183-192;

[0043] The sequence of the N-terminus or C-terminus of the HPV18-E5 protein is SEQ ID NO: 215-224;

[0044] The sequence of the N-terminus or C-terminus of the HPV16-E6 protein is SEQ ID NO: 193-202;

[0045] The sequence of the N-terminus or C-terminus of the HPV18-E6 protein is SEQ ID NO: 225-236;

[0046] The sequence of the N-terminus or C-terminus of the HPV16-E7 protein is SEQ ID NO: 203-214;

[0047] The sequence of the N-terminus or C-terminus of the HPV18-E7 protein is SEQ ID NO: 237-246.

[0048] Preferably, the HPV16-E5 protein consists of the sequence shown in SEQ ID NO: 177;

[0049] And / or, the HPV16-E6 protein consists of the sequence shown in SEQ ID NO: 178;

[0050] And / or, the HPV16-E7 protein consists of the sequence shown in SEQ ID NO: 179;

[0051] And / or, the HPV18-E5 protein consists of the sequence shown in SEQ ID NO: 180;

[0052] And / or, the HPV18-E6 protein consists of the sequence shown in SEQ ID NO: 181;

[0053] And / or, the HPV18-E7 protein consists of the sequence shown in SEQ ID NO:182.

[0054] In the present invention, the preferred antigen protein basic sequence has better adaptability. It is respectively obtained by collecting the protein sequences of E5, E6 and E7 genes of all known HPV16 and HPV18, deduplicating them to reduce regional sampling bias, and then removing incomplete sequences according to the length limit of human protein sequences, and then performing multiple sequence alignment on all sequences of each gene of each type of HPV, and finally selecting the fragment with the highest coverage as the basic sequence to increase adaptability.

[0055] Further, in the present invention, the polypeptide encoded by the coding region includes an amino acid fragment derived from HPV16-E5 protein, an amino acid fragment derived from HPV16-E6 protein, an amino acid fragment derived from HPV16-E7 protein, an amino acid fragment derived from HPV18-E5 protein, an amino acid fragment derived from HPV18-E6 protein, and an amino acid fragment derived from HPV18-E7 protein. The amino acid fragments from each source can be directly fused, truncated fused, truncated fusion connection optimization, or segmented fusion, and the fragments can be connected with or without a linker to construct a polypeptide encoded by the coding region.

[0056] In the present invention, the polypeptide encoded by the coding region is immunogenic.

[0057] In the above-mentioned preferred embodiments, the present invention more preferably truncates the E5, E6 and E7 genes of HPV16 and HPV18 and then fuses them, so that the HPV antigen loses the original carcinogenic biological activity and function of the HPV protein while maintaining that all short peptides of its original sequence can be presented by HLA.

[0058] The truncated fusion proteins, truncated fusion connection optimized proteins or segmented fusion proteins listed in the present invention, the E5 proteins, E6 proteins and E7 proteins of HPV16 and 18 translated by them no longer have the functional inhibitory effect on tumor suppressor genes such as p53 and pBR, are safer, and will not destroy the function of being presented by HLA.

[0059] The truncated fusion connection optimized protein listed in the present invention helps to increase the efficiency of each peptide segment presented by HLA-I and improve the drug effect.

[0060] Further preferably, the polypeptide encoded by the coding region further comprises a secretion signal peptide;

[0061] Preferably, the amino acid sequence of the secretory signal peptide is shown in any one of SEQ ID NOs: 122-146.

[0062] Further preferably, the polypeptide encoded by the coding region also comprises immune cell differentiation, activation and proliferation immunomodulatory molecules;

[0063] Preferably, the amino acid sequence of the immune cell differentiation, activation and proliferation immunomodulatory molecule is as shown in any one of SEQ ID NOs: 147-157.

[0064] Further preferably, the polypeptide encoded by the coding region also contains a universal T epitope that enhances cellular immunity;

[0065] Preferably, the amino acid sequence of the universal T epitope for enhancing cellular immunity is shown in any one or more of SEQ ID NOs: 158-173.

[0066] More preferably, the amino acid sequence of the polypeptide encoded by the coding region is shown in any one of SEQ ID NOs: 247-288.

[0067] In the present invention, the co-expression of the E5 / E6 / E7 fusion polypeptide, the signal peptide of the secretion signal sequence and the immune enhancing peptide increases the effectiveness of the antigen-specific immune response and can more effectively inhibit tumor size compared to the expression of the E5 / E6 / E7 fusion polypeptide alone.

[0068] Furthermore, in the present invention, the RNA molecule may be an artificially synthesized RNA molecule or an in vitro transcribed (IVT-mRNA) mRNA.

[0069] Preferably, the RNA molecule consists of any one of SEQ ID NOs: 289-319.

[0070] In the preferred embodiment provided by the present invention, the RNA molecule is used as a new type of therapeutic mRNA vaccine for cervical cancer targeting the oncogenes E5, E6 and E7 of high-risk HPV16 and HPV18, and its advantages include transient expression and non-transformation characteristics: mRNA does not need to enter the cell nucleus for expression, so mRNA will not be integrated into the host genome, thereby eliminating the risk of tumor occurrence; when used for vaccination, the injection of mRNA can simultaneously induce cellular and humoral immune responses in the body, thereby improving the tumor immunity effect.

[0071] Other nucleotide sequences that are at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the RNA molecules described in the present invention are also within the scope of protection of the present invention.

[0072] In a third aspect, the present invention provides a protein molecule, which is consistent with the amino acid sequence encoded by any of the preceding RNA molecules, or has an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical.

[0073] Alternatively, the constituent sequence of the protein molecule comprises:

[0074] The ORF encodes a polypeptide, wherein the ORF encodes a polypeptide including a signal peptide, a target antigen and an immune enhancing polypeptide molecule, wherein the amino acid sequence of the immune enhancing polypeptide molecule includes at least one of the amino acid sequences shown in SEQ ID NOs: 122-146;

[0075] Preferably, the immune enhancing polypeptide molecule comprises an immune cell differentiation, activation and proliferation immunomodulatory molecule, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 147-157;

[0076] Preferably, the immune enhancing polypeptide molecule comprises a universal T epitope for enhancing cellular immunity, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 158-173.

[0077] Alternatively, the constituent sequence of the protein molecule comprises:

[0078] The ORF encodes a polypeptide, wherein the ORF encodes a polypeptide including a signal peptide, a target antigen and an immune enhancing polypeptide molecule; wherein the ORF encodes a polypeptide including an amino acid fragment derived from HPV E5 protein, and further comprising:

[0079] Amino acid fragments derived from HPV E6 protein; and / or

[0080] Amino acid fragments derived from HPV E7 protein.

[0081] Preferably,

[0082] The HPV E5 protein is selected from HPV16-E5 protein and / or HPV18-E5 protein;

[0083] The HPV E6 protein is selected from HPV16-E6 protein and / or HPV18-E6 protein;

[0084] The HPV E7 protein is selected from HPV16-E7 protein and / or HPV18-E7 protein.

[0085] More preferably,

[0086] The HPV E5 protein is selected from the N-terminus or C-terminus of the HPV16-E5 protein and / or the HPV18-E5 protein;

[0087] The HPV E6 protein is selected from the N-terminus or C-terminus of the HPV16-E6 protein and / or the HPV18-E6 protein;

[0088] The HPV E7 protein is selected from the N-terminus or C-terminus of the HPV16-E7 protein and / or the HPV18-E7 protein.

[0089] More preferably,

[0090] The sequence of the N-terminus or C-terminus of the HPV16-E5 protein is SEQ ID NO: 183-192;

[0091] The sequence of the N-terminus or C-terminus of the HPV18-E5 protein is SEQ ID NO: 215-224;

[0092] The sequence of the N-terminus or C-terminus of the HPV16-E6 protein is SEQ ID NO: 193-202;

[0093] The sequence of the N-terminus or C-terminus of the HPV18-E6 protein is SEQ ID NO: 225-236;

[0094] The sequence of the N-terminus or C-terminus of the HPV16-E7 protein is SEQ ID NO: 203-214;

[0095] The sequence of the N-terminus or C-terminus of the HPV18-E7 protein is SEQ ID NO: 237-246.

[0096] More preferably, the overlapping region between amino acid fragments from the same protein is at least 8 amino acids;

[0097] More preferably, the HPV16-E5 protein consists of the sequence shown in SEQ ID NO: 177, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity;

[0098] and / or, the HPV16-E6 protein consists of the sequence shown in SEQ ID NO: 178, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity;

[0099] and / or, the HPV16-E7 protein consists of the sequence shown in SEQ ID NO: 179, or an amino acid sequence having at least 60%, at least 65%, 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity;

[0100] and / or, the HPV18-E5 protein consists of the sequence shown in SEQ ID NO: 180, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity;

[0101] and / or, the HPV18-E6 protein consists of the sequence shown in SEQ ID NO: 181, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity;

[0102] And / or, the HPV18-E7 protein consists of the sequence shown in SEQ ID NO:182, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity.

[0103] More preferably, the amino acid sequence of the immune enhancing polypeptide molecule includes at least one of the amino acid sequences shown in SEQ ID NO: 122-146;

[0104] Preferably, the immune enhancing polypeptide molecule comprises an immune cell differentiation, activation and proliferation immunomodulatory molecule, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 147-157;

[0105] Preferably, the immune enhancing polypeptide molecule comprises a universal T epitope for enhancing cellular immunity, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 158-173.

[0106] Preferably, the amino acid sequence of the protein molecule is shown in any one of SEQ ID NOs: 247-288.

[0107] In a fourth aspect, the present invention provides a nucleic acid molecule comprising a DNA molecule having a nucleotide sequence corresponding to the nucleotide sequence of the RNA molecule described above.

[0108] In a fifth aspect, the present invention provides a pharmaceutical composition, which comprises a pharmacological component, such as the RNA molecule, or the protein molecule, or the DNA nucleic acid molecule; and a pharmaceutically acceptable delivery carrier, such as a conventional viral vector, lipid nanoparticle, polymer nanocarrier, inorganic nanocarrier, protein carrier, exosome, etc. The pharmacological component molecules and the delivery system together constitute a passive immunization preparation for preventing or treating HPV-related diseases.

[0109] In one of the more specific embodiments provided by the present invention, the delivery carrier is a lipid nanoparticle. The lipid nanoparticle can be a commercially available lipid nanoparticle conventional or known in the art, or a lipid nanoparticle prepared by a conventional or known method in the art. For example, the lipid nanoparticle disclosed in Chinese Patent Application No. 202410691595.3 or 2024100944789 can be used.

[0110] Preferably, the pharmaceutical composition is in the form of an injection, a lyophilized agent, a spray, a capsule, a tablet or a patch.

[0111] In a sixth aspect, the present invention provides the use of the RNA molecule, or the protein molecule, or the DNA nucleic acid molecule, or the pharmaceutical composition in preventing or treating HPV-related diseases.

[0112] Preferably, the HPV-related diseases include HPV16 and / or HPV18-positive related diseases.

[0113] Preferably, the HPV16 and / or HPV18 positive diseases are precancerous lesions, warts and cancer-related diseases.

[0114] Preferably, the HPV-related diseases include at least one of cervical intraepithelial neoplasia, cervical cancer, papillomavirus infection, head and neck tumors, oropharyngeal cancer, laryngeal cancer, vulvar cancer, penile cancer, vaginal cancer, anal cancer, condyloma acuminatum, squamous cell carcinoma, glioblastoma, ovarian cancer and herpetic keratitis.

[0115] In a seventh aspect, the present invention provides the use of the RNA molecule, or the protein molecule, or the DNA nucleic acid molecule, or the pharmaceutical composition in the preparation of a drug for preventing or treating HPV-related diseases.

[0116] Preferably, the HPV-related diseases include HPV16 and / or HPV18-positive related diseases.

[0117] Preferably, the HPV16 and / or HPV18 positive diseases are precancerous lesions, warts and cancer-related diseases.

[0118] Preferably, the HPV-related diseases include at least one of cervical intraepithelial neoplasia, cervical cancer, papillomavirus infection, head and neck tumors, oropharyngeal cancer, laryngeal cancer, vulvar cancer, penile cancer, vaginal cancer, anal cancer, condyloma acuminatum, squamous cell carcinoma, glioblastoma, ovarian cancer and herpetic keratitis.

[0119] In an eighth aspect, the present invention further provides the use of the 5'UTR and / or 3'UTR of the RNA molecule for efficiently translating the coding region of the RNA molecule into a polypeptide or protein encoded by the coding region.

[0120] Beneficial effects:

[0121] The present invention provides a nucleic acid molecule, a polypeptide, a protein, a related product and a use. The RNA molecule involved is based on a UTR composed of a specific sequence and can efficiently express a target gene. In addition, the nucleic acid molecule and its corresponding polypeptide, protein and related product provided by the present invention target the oncogenes E5, E6 and E7 of high-risk HPV16 and HPV18, and can be used as a therapeutic vaccine for HPV-related diseases (such as cervical cancer), with a wide range of targets, a higher coverage rate of disease populations, strong immunogenicity, the ability to fully activate cellular immunity, and good product efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0122] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.

[0123] Figure 1 The comparison results of the overall expression of EGFP protein with different UTR sequences in Example 1 of the present invention are shown.

[0124] Figure 2 The fluorescence intensity of EGFP protein expression with different UTR sequences in Example 1 of the present invention is greater than 1×10 6 Comparison results of cell percentages.

[0125] Figure 3 This is the expression verification result of mRNA without Poly A in Example 2 of the present invention.

[0126] Figure 4 The results are a comparison of the expression levels of different mRNA proteins in Huh-7 cells in Example 3 of the present invention.

[0127] Figure 5 The results are a comparison of the expression levels of different mRNA proteins in HEK293 cells in Example 3 of the present invention.

[0128] Figure 6 The figure shows the comparison of the inhibition of tumor growth between HX22-02 and HX22-03 in Example 4 of the present invention in the in vivo mouse experiment.

[0129] Figure 7 The figure is a comparison of the inhibition of tumor growth by HX22-11 in the in vivo mouse experiment in Example 4 of the present invention.

[0130] Figure 8 The figure is a comparison of the inhibition of tumor growth by HX22-12 in the in vivo mouse experiment in Example 4 of the present invention.

[0131] Fig. 9 The figure is a comparison of the inhibition of tumor growth by HX22-14 in Example 4 of the present invention in an in vivo mouse experiment.

[0132] Fig.10 The figure is a comparison of the inhibition of tumor growth by HX22-16 in the mouse in vivo experiment in Example 4 of the present invention.

[0133] Fig.11 The figure is a comparison of the inhibition of tumor growth by HX22-22 and HX22-27 in Example 4 of the present invention in an in vivo mouse experiment. DETAILED DESCRIPTION

[0134] The technical solutions provided by the present invention are described in detail below in conjunction with the examples, but they should not be understood as limiting the scope of protection of the present invention. Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials and reagents used can be obtained from commercial sources.

[0135] In addition, in order to make the content of the present invention more concise, the DNA molecules corresponding to the RNA molecules listed below are not listed. Those skilled in the art can derive the corresponding DNA molecule sequences based on the conversion rules between RNA molecules and DNA molecules.

[0136] Example 1 UTR sequence confirmation and sequence screening

[0137] (1) UTR sequence confirmation.

[0138] According to the UTR translation efficiency evaluation model designed by the inventor, a translation efficiency score table was obtained, and then the 18 5'UTR sequences with the highest scores were finally obtained by screening by sequence length, secondary structure, free energy and other energy numbers. These 18 5'UTR sequences (mRNA, 5'→3') are specifically shown in SEQ ID NOs: 1 to 18.

[0139] The core fragment of 3'UTR consists of two parts.

[0140] The first part is the 3'UTR upstream sequence. The 3'UTR upstream sequence (mRNA, 5'→3') is specifically shown in SEQ ID NOs: 19-27.

[0141] The second part is the 3'UTR downstream sequence. The 3'UTR downstream sequence (mRNA, 5'→3') is specifically shown in SEQ ID NOs: 28-39.

[0142] Because Poly(A) will naturally degrade in the human body, the existing UTR may face the situation of Poly(A) degradation in the human body, which directly leads to reduced translation efficiency or failure to translate. To solve this problem, this technical solution uses a 3'UTR containing histones as downstream sequences, which can directly initiate translation without relying on Poly(A).

[0143] (2) Construction of mRNA in vitro transcription plasmid.

[0144] In this embodiment, when testing the effect of different UTR combinations on gene protein translation efficiency, mRNA was transfected into eukaryotic cells, and the fluorescence signal intensity of the fluorescent protein was compared to screen out the best UTR combination.

[0145] Generally, linear mRNA requires Poly A during translation; the present invention preferably adopts a Poly A strategy of 0-150 A; for example, most mRNA sequences in this embodiment adopt a Poly A strategy of 150 A. The Poly A sequence of 150 A (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 40.

[0146] The fluorescent protein genes used are enhanced green fluorescent protein (EGFP) gene and firefly luciferase (Firefly luciferase) gene. The amino acid sequence (N'→C') of EGFP is specifically shown in SEQ ID NO: 41; the amino acid sequence (N'→C') of Firefly luciferase is specifically shown in SEQ ID NO: 42.

[0147] In order to reduce the side effects of target genes (especially cytokines that cause immune responses), the introduction of a complete or partial matching sequence of an organ-specific highly expressed miRNA in the 3'UTR can promote the degradation of mRNA drugs in these organs. The mRNA sequence of the present invention may also include 0 sequences or at least one sequence in the target sequence of the tissue-specific highly expressed miRNA. The target sequence of the tissue-specific highly expressed miRNA (mRNA, 5'→3') is specifically shown in SEQ ID NO: 43-110, see Table 1 for details.

[0148] Table 1

[0149]

[0150]

[0151]

[0152] The designed different 5'UTR, 3'UTR, miRNA and Poly A sequences were synthesized and constructed into a cloning plasmid vector by cloning. At the same time, the enhanced green fluorescent protein EGFP was seamlessly cloned into the above constructed vector, and the insertion site was between the 5'UTR and 3'UTR, so as to obtain plasmids carrying different 5'UTR and 3'UTR sequences, but all of which could express EGFP protein through in vitro transcription.

[0153] (3) Plasmid extraction and linearization.

[0154] The plasmid obtained in (2) was transformed into the E. coli DH5α strain to obtain a recombinant strain. On the second day, three monoclonal colonies were selected from the growth plates of different plasmid strains, and the monoclonal colonies with correct sequences and Poly A greater than or equal to 110A were transferred to 200 ml of LB medium and cultured overnight in a constant temperature shaker at 37°C and 150 rpm. The bacterial cells were harvested on the second day, and the plasmid was extracted using a plasmid extraction kit.

[0155] The plasmid obtained above was digested with restriction endonuclease BsaI at 37°C overnight, and the digested plasmid was purified and recovered using magnetic beads the next day. The purified and recovered linearized plasmid can be directly used as a template for subsequent mRNA in vitro transcription.

[0156] (4) In vitro transcription and purification of mRNA.

[0157] The linearized plasmid obtained in (3) was used as a template for in vitro transcription of mRNA, and mRNA was obtained by in vitro transcription using an mRNA in vitro transcription kit. After in vitro transcription was completed, DNaseI with a final concentration of 0.15 U / μl was added to the reaction system, and the reaction was carried out at 37°C for 30 minutes to digest the DNA template in the reaction system. The mRNA obtained by in vitro transcription was then purified and concentrated using magnetic bead purification to obtain the full sequences of different mRNAs.

[0158] The full mRNA sequence obtained in this part contains at least one sequence in the 5'UTR sequence list, at least one sequence in the 3'UTR sequence list, 0 sequences or at least one sequence in the target sequence list of tissue-specific highly expressed miRNA, and does not contain Ploy A sequence or contains 1-200 Ploy A sequences.

[0159] Some example sequences are as follows:

[0160] UTR-01, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 111;

[0161] UTR-02, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 112;

[0162] UTR-03, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 113;

[0163] UTR-04, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 114;

[0164] UTR-05, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 115;

[0165] UTR-06, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 116;

[0166] UTR-07, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 117;

[0167] UTR-08, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 118;

[0168] UTR-09, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 119;

[0169] UTR-10, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 120;

[0170] UTR-11, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO:121.

[0171] (5) Comparison of mRNA expression efficiency containing different UTR sequences.

[0172] In this example, the mRNA obtained by in vitro transcription was transfected into HEK293 cells to compare the protein translation efficiency of different UTR combinations. An existing product (Company B UTR) was used as a control.

[0173] The specific steps are:

[0174] 1×10 cells were seeded into each well of a 12-well plate. 5 HEK293 cells were then cultured in a cell culture incubator.

[0175] Observe the cells the next day and prepare for mRNA transfection when the cell density reaches 80%-90%.

[0176] Take 10 sterile centrifuge tubes and add 100 μL of culture medium, then divide them into two groups. Add 2.0 μg of different mRNA to 5 tubes in one group, and add 6.0 μl of lipofectamine to 5 tubes in the other group. TM 3000. Then equilibrate for 5 min.

[0177] After the balance is completed, the liquids in the two sets of corresponding numbered centrifuge tubes are evenly mixed and incubated at room temperature for 10-15 minutes to form mRNA-Lipofectamine TM3000 polymers.

[0178] After the incubation, add it to the corresponding cell plate, mix well, and then put the cells back into the cell culture incubator to continue culturing for 24 hours.

[0179] After 24 h, the cells were harvested and the fluorescence intensity of the cells was detected by flow cytometry, and the overall fluorescence intensity of the cells was detected respectively.

[0180] By comparing the mRNA expression efficiency of different UTR sequences, the results show that the fluorescent protein translation efficiency of the UTR of all exemplary combinations of the present invention is higher than that of Company B ( Figure 1 ).

[0181] By comparing the mRNA expression efficiency of different UTR sequences, the fluorescence intensity was greater than 1x10 6 The percentage of cells showed that the fluorescent protein translation efficiency of the UTR of all example combinations was higher than that of company B ( Figure 2 ).

[0182] Example 2 Verification of protein translation in the absence of Poly A in 3'UTR

[0183] This example uses the firefly luciferase gene to verify the protein translation efficiency of different UTR combinations in Example 1 when Poly A is missing. Taking UTR-06 as an example, this example transfects the mRNA (UTR-06) obtained by in vitro transcription into HEK293 cells, and uses a microplate reader to detect the cell fluorescence intensity at different time points to verify the protein translation of the mRNA.

[0184] The specific steps are:

[0185] Cell seeding: HEK293 cells were seeded in 96-well plates at a density of 1×10 5 cells / well, volume is 100ul.

[0186] mRNA transfection: using Lipofectamine TM The mRNA was transfected into the cells using Lipo3000 reagent, 0.1 μg of mRNA and 2.5 μl of Lipo3000.

[0187] Fluorescence detection: Use an ELISA reader for luminescence detection at different time points with a luminescence gain of 212. Add 20ul of Luciferase to each well and shake gently for detection.

[0188] Data analysis: The detected data are summarized and analyzed in charts. Figure 3 .

[0189] The experimental results show that the 3'UTR designed by the present invention can still translate proteins to a certain extent in the absence of the PloyA structure.

[0190] Example 3 Effect of 3'UTR on protein expression after miRNA target sequence modification

[0191] The 3'UTR designed by the present invention combines the specific tissue-specific high-expression miRNA target sequence obtained by the present invention screening, produces a new type of 3'UTR, and includes the mRNA of this new type 3'UTR, which can reduce the content in specific tissues, thereby reducing the expression of the target gene in specific tissues, thereby reducing the off-target toxicity of the target gene. The present embodiment uses UTR-07 and UTR-08 as experimental groups, and uses the sequence (UTR-11) of the mRNA of the miRNA target sequence that is not included in the specific high expression in the liver as a control group, and verifies the influence of the 3'UTR after the transformation of the miRNA target sequence on protein expression. Because the verification of the influence of the 3'UTR after the transformation on protein expression needs to be carried out in vitro cells and animals at the same time, so the experimental verification of the influence of the 3'UTR after the transformation on protein expression in the present embodiment still uses the firefly luciferase (Firefly luciferase) gene, and the specific experimental scheme and detection method refer to Example 1 and Example 2.

[0192] The experimental results are shown in Figure 4 and Figure 5 .

[0193] Depend on Figure 4 It can be seen that compared with the mRNA sequence (UTR-11) that does not contain the miRNA target sequence that is specifically highly expressed in the liver, the mRNA sequence (UTR07, UTR-08) that contains the miRNA target sequence that is specifically highly expressed in the liver in the 3'UTR has a reduced expression level of fluorescent protein in the liver cancer cell line Huh-7.

[0194] Depend on Figure 5 It can be seen that in the cell line HEK293 that low-expresses the corresponding miRNA, the fluorescent protein expression levels of UTR07 and UTR-08 are not lower than that of UTR-11, but are higher.

[0195] Example 4 Acquisition, optimization and mRNA synthesis of antigen sequences

[0196] (1) Confirmation of immune-enhancing sequences

[0197] In order to increase the immunogenicity of the antigen sequence, in this embodiment, a secretion signal peptide sequence (such as TPA) is added to the N-terminus of the antigen sequence, so that the target protein synthesized in the cell can be secreted to the extracellular space to enhance MHC-II class presentation.

[0198] The optional secretion signal peptide sequences (amino acid sequence, N'→C') of the present invention are specifically shown in SEQ ID NOs: 122-146.

[0199] To further enhance the immune response, this embodiment adds immune cell differentiation, activation and proliferation regulatory molecules to the antigen sequence.

[0200] The optional immune cell differentiation, activation and proliferation regulatory molecule sequences (amino acid sequence, N'→C') of the present invention are specifically shown in SEQ ID NOs: 147-157.

[0201] In addition, this example also enhances the immunogenicity of the vaccine by adding an immunogenic T cell polypeptide epitope to the C-terminus of the antigen sequence.

[0202] The optional universal T epitope sequence (amino acid sequence, N'→C') for enhancing cellular immunity of the present invention is specifically shown in SEQ ID NOs: 158-173.

[0203] In this embodiment, the amino acid sequence (N'→C') of the sequence tandem linker is specifically shown in SEQ ID NOs: 174-176.

[0204] (2) Obtaining antigen sequences.

[0205] This example screened big data and compared literature sequences using bioinformatics methods to obtain the basic amino acid sequences of E5, E6, and E7 of HPV16 and HPV18, including:

[0206] HPV16-E5, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 177;

[0207] HPV16-E6, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 178;

[0208] HPV16-E7, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 179;

[0209] HPV18-E5, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 180;

[0210] HPV18-E6, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 181;

[0211] HPV18-E7, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 182;

[0212] The present invention obtains multiple candidate antigen amino acid sequences through different combinations.

[0213] The combination methods include direct fusion, truncation and fusion, truncation fusion connection optimization, and segmented fusion.

[0214] After combination, the specific HPV antigen epitope includes the N-terminal and C-terminal sequences of at least one of the sequences of SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, and SEQ ID NO: 182.

[0215] For example, the truncated antigen epitope amino acid sequence (N'→C') derived from HPV16-E5 can be selected from the amino acid sequences shown in SEQ ID NOs: 183 to 192; the truncated antigen epitope amino acid sequence (N'→C') derived from HPV16-E6 can be selected from the amino acid sequences shown in SEQ ID NOs: 193 to 202; the truncated antigen epitope amino acid sequence (N'→C') derived from HPV16-E7 can be selected from the amino acid sequences shown in SEQ ID NOs: 203 to 214; the truncated antigen epitope amino acid sequence (N'→C') derived from HPV18-E5 can be selected from the amino acid sequences shown in SEQ ID NOs: 215 to 224; the truncated antigen epitope amino acid sequence (N'→C') derived from HPV18-E6 can be selected from the amino acid sequences shown in SEQ ID NOs: 225 to 236; the truncated antigen epitope amino acid sequence (N'→C') derived from HPV18-E7 can be selected from the amino acid sequences shown in SEQ ID NOs: 237 to 246.

[0216] Some examples of combined sequences (antigen amino acid sequences after fusion) are as follows:

[0217] HPV_01, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 247;

[0218] HPV_02, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 248;

[0219] HPV_03, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 249;

[0220] HPV_04, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 250;

[0221] HPV_05, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 251;

[0222] HPV_06, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 252;

[0223] HPV_07, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 253;

[0224] HPV_08, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 254;

[0225] HPV_09, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 255;

[0226] HPV_10, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 256;

[0227] HPV_11, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 257;

[0228] HPV_12, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 258;

[0229] HPV_13, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 259;

[0230] HPV_14, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 260;

[0231] HPV_15, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 261;

[0232] HPV_16, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 262;

[0233] HPV_17, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 263;

[0234] HPV_18, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 264;

[0235] HPV_19, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 265;

[0236] HPV_20, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 266;

[0237] HPV_21, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 267;

[0238] HPV_22, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 268;

[0239] HPV_23, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 269;

[0240] HPV_24, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 270;

[0241] HPV_25, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 271;

[0242] HPV_26, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 272;

[0243] HPV_27, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 273;

[0244] HPV_28, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 274;

[0245] HPV_29, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 275;

[0246] HPV_30, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 276;

[0247] HPV_31, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 277;

[0248] HPV_32, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 278;

[0249] HPV_33, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 279;

[0250] HPV_34, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 280;

[0251] HPV_35, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 281;

[0252] HPV_36, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 282;

[0253] HPV_37, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 283;

[0254] HPV_38, the sequence of which (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 284;

[0255] HPV_39, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 285;

[0256] HPV_40, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 286;

[0257] HPV_41, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO: 287;

[0258] HPV_42, whose sequence (amino acid sequence, N'→C') is specifically shown in SEQ ID NO:288.

[0259] (2) Detection of the efficacy of mRNA drugs containing HPV antigen sequences.

[0260] After the HPV antigen sequences in (1) are codon optimized, plasmids and mRNAs are constructed by the scheme described above in the present invention. This part of the sequence contains at least one sequence in the 5'UTR sequence table, at least one sequence in the 3'UTR sequence table, 0 sequences or at least one sequence in the target sequence table of tissue-specific highly expressed miRNA, and does not contain a PloyA sequence or contains 80-150 Ploy A sequences. At the same time, the amino acid sequence obtained by translating this part of the sequence contains the following sequences: contains an HPV antigen combination epitope sequence; does not contain a sequence in the signal peptide table, or contains at least one sequence in the signal peptide table; does not contain an immune cell differentiation, activation and proliferation regulatory molecule sequence, or contains at least one immune cell differentiation, activation and proliferation regulatory molecule sequence; does not contain a universal T epitope sequence that enhances cellular immunity, or contains at least one universal T epitope sequence that enhances cellular immunity; does not contain a sequence tandem linker sequence, or contains at least one sequence tandem linker sequence.

[0261] Some examples of full mRNA sequences (5'→3') containing HPV antigen sequences are as follows:

[0262] HX22-01, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 289;

[0263] HX22-02, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 290;

[0264] HX22-03, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 291;

[0265] HX22-04, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 292;

[0266] HX22-05, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 293;

[0267] HX22-06, whose sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 294;

[0268] HX22-07, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 295;

[0269] HX22-08, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 296;

[0270] HX22-09, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 297;

[0271] HX22-10, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 298;

[0272] HX22-11, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 299;

[0273] HX22-12, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 300;

[0274] HX22-13, the sequence (mRNA sequence, 5'→3') of which is specifically shown in SEQ ID NO: 301;

[0275] HX22-14, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 302;

[0276] HX22-15, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 303;

[0277] HX22-16, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 304;

[0278] HX22-17, the sequence (mRNA sequence, 5'→3') of which is specifically shown in SEQ ID NO: 305;

[0279] HX22-18, the sequence (mRNA sequence, 5'→3') of which is specifically shown in SEQ ID NO: 306;

[0280] HX22-19, the sequence (mRNA sequence, 5'→3') of which is specifically shown in SEQ ID NO: 307;

[0281] HX22-20, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 308;

[0282] HX22-21, the sequence (mRNA sequence, 5'→3') of which is specifically shown in SEQ ID NO: 309;

[0283] HX22-22, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 310;

[0284] HX22-23, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 311;

[0285] HX22-24, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 312;

[0286] HX22-25, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 313;

[0287] HX22-26, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 314;

[0288] HX22-27, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 315;

[0289] HX22-28, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 316;

[0290] HX22-29, the sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 317;

[0291] HX22-30, the sequence of which (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO: 318;

[0292] HX22-31, its sequence (mRNA sequence, 5'→3') is specifically shown in SEQ ID NO:319.

[0293] In this embodiment, the prepared mRNA is encapsulated by LNP: ionizable lipids, DSPC, cholesterol and DMG-PEG2000 are dissolved in anhydrous ethanol according to a fixed formula molar ratio, that is, the ethanol phase; the mRNA drug is dissolved in a sodium acetate solution, that is, the aqueous phase; the ethanol phase and the aqueous phase are respectively inserted into the two ends of the microfluidic chip with sterile syringes, and the ethanol phase and the aqueous phase are mixed by a microfluidic device, and the ratio is controlled to be 1:3 by volume ratio of the ethanol phase to the aqueous phase, and the lipid nanoparticle solution. Using ultrafiltration technology, ultrafiltration is performed with Tris-HCl solution to remove ethanol and some small molecule impurities. Then, the prepared mRNA-new LNP drug is quality controlled, mainly including parameters such as encapsulation rate, particle size and Zeta potential, wherein the encapsulation rate is greater than 90%, the particle size is about 60-120nm, Zeta is between ±30, and the polydispersity coefficient PDI is less than 0.2.

[0294] After the prepared mRNA is encapsulated by LNP, its tumor-clearing effect is detected using a mouse subcutaneous tumor animal model. The positive control group used in the animal experiment of the present invention is the sequence in the patent (CN107073070A). After the sequence in the patent is extracted, it is prepared into an mRNA drug using the same scheme used in the present invention.

[0295] The specific steps of animal experiments are as follows:

[0296] TC-1 (C57BL / 6J immortalized cell line that can stably express HPV16_E6 and HPV16_E7 proteins) was cultured and expanded.

[0297] Mouse tumor model was established. TC-1 cells (1×10 5 cells, 100ul) were injected subcutaneously into 4-6 week old C57BL / 6J mice, which were then kept in an SPF environment.

[0298] When the subcutaneous tumor grew to the size of a soybean, the mice were randomly divided into groups.

[0299] Different groups received different drugs by intramuscular injection. The mRNA drug injection time was 6-10 days after subcutaneous tumor cell inoculation in mice. The injection frequency was three injections, with an interval of 7 days between each injection. The injection dose was 5 mg / injection.

[0300] The tumor size of mice was measured with a vernier caliper twice or three times a week and statistically analyzed.

[0301] Comparison of different mRNAs in inhibiting tumor growth in mice in vivo Figure 6-Figure 11 .

[0302] The results of the tumor inhibition effect on mice showed that when compared with the negative control group (Irrelevant mRNA), the mRNA designed by the present invention can significantly inhibit the tumor growth of the tumor-bearing mouse model, and when compared with the positive control group (G company HPV mRNA), the two mRNAs designed by the present invention also have better tumor inhibition effects.

[0303] The above-mentioned embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solution of the present invention in detail, but it cannot be understood as limiting the scope of the invention patent protection. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. An RNA molecule, characterized in that Include: (a) a coding region encoding a polypeptide; and (b) a 5'UTR upstream of the coding region; and (c) a 3'UTR downstream of the coding region; The constituent sequence of the 3'UTR comprises a nucleotide fragment derived from a histone gene; Preferably, the 3'UTR downstream sequence is derived from a nucleotide fragment of a histone gene, and the nucleotide fragment is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 28-39; Preferably, the 3'UTR upstream sequence is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 19-27; Preferably, the constituent sequence of the 3'UTR further comprises a miRNA target sequence; Preferably, the miRNA target sequence is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 43-110; Preferably, the nucleotide fragment of the 5'UTR is selected from at least one of the nucleotide sequences shown in SEQ ID NOs: 1-18; Preferably, the RNA molecule further comprises: (d) a polyadenylic acid tail at the 3' end; Preferably, the length of the poly(A) tail is 0-200 bp; more preferably, the length is 0-150 bp; Preferably, the nucleotide sequence of the RNA molecule is as shown in any one of SEQ ID NOs: 111-121.

2. RNA molecule, characterized in that Include: (a) a coding region encoding a polypeptide; and (b) a 5'UTR upstream of the coding region; and (c) a 3'UTR downstream of the coding region; The polypeptide encoded by the coding region comprises an amino acid fragment derived from HPV E5 protein, and further comprises: Amino acid fragments derived from HPV E6 protein; and / or Amino acid fragments derived from HPV E7 protein; Preferably, The amino acid sequence of the HPV E5 protein is selected from the amino acid sequence of the HPV16-E5 protein and / or the amino acid sequence of the HPV18-E5 protein; The amino acid sequence of the HPV E6 protein is selected from the group consisting of the amino acid sequence of the HPV16-E6 protein and / or the amino acid sequence of the HPV18-E6 protein; The amino acid sequence of the HPV E7 protein is selected from the amino acid sequence of the HPV16-E7 protein and / or the amino acid sequence of the HPV18-E7 protein; Preferably, The HPV E5 protein is selected from the N-terminus or C-terminus of the HPV16-E5 protein and / or the HPV18-E5 protein; The HPV E6 protein is selected from the N-terminus or C-terminus of the HPV16-E6 protein and / or the HPV18-E6 protein; The HPV E7 protein is selected from the N-terminus or C-terminus of the HPV16-E7 protein and / or the HPV18-E7 protein; Preferably, the sequence of the N-terminus or C-terminus of the HPV16-E5 protein is SEQ ID NO: 183-192; The sequence of the N-terminus or C-terminus of the HPV18-E5 protein is SEQ ID NO: 215-224; The sequence of the N-terminus or C-terminus of the HPV16-E6 protein is SEQ ID NO: 193-202; The sequence of the N-terminus or C-terminus of the HPV18-E6 protein is SEQ ID NO: 225-236; The sequence of the N-terminus or C-terminus of the HPV16-E7 protein is SEQ ID NO: 203-214; The sequence of the N-terminus or C-terminus of the HPV18-E7 protein is SEQ ID NO: 237-246; Preferably, the amino acid sequence of the HPV16-E5 protein consists of the sequence shown in SEQ ID NO: 177; And / or, the HPV16-E6 protein consists of the sequence shown in SEQ ID NO: 178; And / or, the HPV16-E7 protein consists of the sequence shown in SEQ ID NO: 179; And / or, the HPV18-E5 protein consists of the sequence shown in SEQ ID NO: 180; And / or, the HPV18-E6 protein consists of the sequence shown in SEQ ID NO: 181; And / or, the HPV18-E7 protein consists of the sequence shown in SEQ ID NO: 182; Preferably, the polypeptide encoded by the coding region further comprises a secretion signal peptide; Preferably, the amino acid sequence of the secretory signal peptide is shown in any one of SEQ ID NOs: 122-146; Preferably, the polypeptide encoded by the coding region further comprises immune cell differentiation, activation and proliferation immunomodulatory molecules; Preferably, the amino acid sequence of the immune cell differentiation, activation and proliferation immunomodulatory molecule is as shown in any one or more of SEQ ID NOs: 147-157; Preferably, the polypeptide encoded by the coding region further comprises a universal T epitope that enhances cellular immunity; Preferably, the amino acid sequence of the universal T epitope for enhancing cellular immunity is shown in any one or more of SEQ ID NOs: 158-173; Preferably, the amino acid sequence of the polypeptide encoded by the coding region is shown in any one of SEQ ID NOs: 247-288; Preferably, the RNA molecule is an artificially synthesized RNA molecule, or an in vitro transcribed RNA molecule; Preferably, the RNA molecule consists of any one of SEQ ID NOs: 289-319.

3. RNA molecule, characterized in that The RNA molecule comprises a nucleotide sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the RNA molecule of claim 1 or 2.

4. A protein molecule, characterized in that An amino acid sequence that is consistent with the amino acid sequence encoded by the RNA molecule of claim 1 or 2; or an amino acid sequence that has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity.

5. A protein molecule, characterized in that The composition sequence of the protein molecule comprises: The ORF encodes a polypeptide, wherein the ORF encodes a polypeptide including a signal peptide, a target antigen and an immune enhancing polypeptide molecule, and the amino acid sequence of the signal peptide includes at least one of the amino acid sequences shown in SEQ ID NOs: 122-146; Preferably, the immune enhancing polypeptide molecule comprises an immune cell differentiation, activation and proliferation immunomodulatory molecule, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 147-157; Preferably, the immune enhancing polypeptide molecule comprises a universal T epitope for enhancing cellular immunity, and its amino acid sequence comprises at least one of the amino acid sequences shown in SEQ ID NO: 158-173; Alternatively, the constituent sequence of the protein molecule comprises: The ORF encodes a polypeptide, wherein the ORF encodes a polypeptide including a signal peptide, a target antigen and an immune enhancing polypeptide molecule; wherein the ORF encodes a polypeptide including an amino acid fragment derived from HPV E5 protein, and further comprising: Amino acid fragments derived from HPV E6 protein; and / or Amino acid fragments derived from HPV E7 protein; Preferably, The amino acid sequence of the HPV E5 protein is selected from the amino acid sequence of the HPV16-E5 protein and / or the amino acid sequence of the HPV18-E5 protein; The amino acid sequence of the HPV E6 protein is selected from the group consisting of the amino acid sequence of the HPV16-E6 protein and / or the amino acid sequence of the HPV18-E6 protein; The amino acid sequence of the HPV E7 protein is selected from the amino acid sequence of the HPV16-E7 protein and / or the amino acid sequence of the HPV18-E7 protein; Preferably, The HPV E5 protein is selected from the N-terminus or C-terminus of the HPV16-E5 protein and / or the HPV18-E5 protein; The HPV E6 protein is selected from the N-terminus or C-terminus of the HPV16-E6 protein and / or the HPV18-E6 protein; The HPV E7 protein is selected from the N-terminus or C-terminus of the HPV16-E7 protein and / or the HPV18-E7 protein; Preferably, The sequence of the N-terminus or C-terminus of the HPV16-E5 protein is SEQ ID NO: 183-192; The sequence of the N-terminus or C-terminus of the HPV18-E5 protein is SEQ ID NO: 215-224; The sequence of the N-terminus or C-terminus of the HPV16-E6 protein is SEQ ID NO: 193-202; The sequence of the N-terminus or C-terminus of the HPV18-E6 protein is SEQ ID NO: 225-236; The sequence of the N-terminus or C-terminus of the HPV16-E7 protein is SEQ ID NO: 203-214; The sequence of the N-terminus or C-terminus of the HPV18-E7 protein is SEQ ID NO: 237-246; Preferably, the overlapping region between amino acid fragments from the same protein is at least 8 amino acids; Preferably, the HPV16-E5 protein consists of the sequence shown in SEQ ID NO: 177, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; and / or, the HPV16-E6 protein consists of the sequence shown in SEQ ID NO: 178, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; and / or, the HPV16-E7 protein consists of the sequence shown in SEQ ID NO: 179, or an amino acid sequence having at least 60%, at least 65%, 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; and / or, the HPV18-E5 protein consists of the sequence shown in SEQ ID NO: 180, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; and / or, the HPV18-E6 protein consists of the sequence shown in SEQ ID NO: 181, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; and / or, the HPV18-E7 protein consists of the sequence shown in SEQ ID NO: 182, or an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity; Preferably, the amino acid sequence of the immune enhancing polypeptide molecule includes at least one of the amino acid sequences shown in SEQ ID NO: 122-173; More preferably, the amino acid sequence of the protein molecule is shown in any one of SEQ ID NOs: 247-288.

6. A nucleic acid molecule, characterized in that It includes a DNA molecule having a nucleotide sequence corresponding to the nucleotide sequence of the RNA molecule according to any one of claims 1-3.

7. A pharmaceutical composition, characterized in that Comprising the RNA molecule according to any one of claims 1 to 3, or the protein molecule according to claim 4 or 5, or the nucleic acid molecule according to claim 6; further comprising a pharmaceutically acceptable drug delivery carrier, such as a viral vector, a lipid nanoparticle, a polymer nanocarrier, an inorganic nanocarrier, a protein carrier, an exosome, etc.; Preferably, the pharmaceutical composition is in the form of an injection, a lyophilized agent, a spray, a capsule, a tablet or a patch.

8. Use of the RNA molecule according to any one of claims 1 to 3, or the protein molecule according to claim 4 or 5, or the nucleic acid molecule according to claim 6, or the pharmaceutical composition according to claim 7 in preventing or treating HPV-related diseases; Preferably, the HPV-related diseases include HPV16 and / or HPV18-positive related diseases; Preferably, the HPV16 and / or HPV18 positive diseases are precancerous lesions, warts and cancer-related diseases; Preferably, the HPV-related diseases include at least one of cervical intraepithelial neoplasia, cervical cancer, papillomavirus infection, head and neck tumors, oropharyngeal cancer, laryngeal cancer, vulvar cancer, penile cancer, vaginal cancer, anal cancer, condyloma acuminatum, squamous cell carcinoma, glioblastoma, ovarian cancer and herpetic keratitis.

9. Use of the RNA molecule according to any one of claims 1 to 3, or the protein molecule according to claim 4 or 5, or the nucleic acid molecule according to claim 6, or the pharmaceutical composition according to claim 7 in the preparation of a drug for preventing or treating HPV-related diseases; Preferably, the HPV-related diseases include HPV16 and / or HPV18-positive related diseases; Preferably, the HPV16 and / or HPV18 positive diseases are precancerous lesions, warts and cancer-related diseases; Preferably, the HPV-related diseases include at least one of cervical intraepithelial neoplasia, cervical cancer, papillomavirus infection, head and neck tumors, oropharyngeal cancer, laryngeal cancer, vulvar cancer, penile cancer, vaginal cancer, anal cancer, condyloma acuminatum, squamous cell carcinoma, glioblastoma, ovarian cancer and herpetic keratitis.

10. Use of the 5'UTR and / or 3'UTR of the RNA molecule according to any one of claims 1 to 3 for improving the efficiency of translating the coding region of the RNA molecule into a polypeptide or protein encoded by the coding region.